1 results match your criteria: "Division of Orthopaedic Surgery The Children's Hospital of Philadelphia Philadelphia PA USA.[Affiliation]"
Palovarotene Action Against Heterotopic Ossification Includes a Reduction of Local Participating Activin A-Expressing Cell Populations.
JBMR Plus
December 2023
Translational Research Program in Pediatric Orthopaedics, Division of Orthopaedic Surgery The Children's Hospital of Philadelphia Philadelphia PA USA.
Article Synopsis
- Heterotopic ossification (HO) is the abnormal formation of bone outside of the skeleton, which can be caused by trauma or genetic conditions like fibrodysplasia ossificans progressiva (FOP).
- Recent studies highlighted that activin A plays a role in promoting both acquired and genetic forms of HO, while palovarotene, a retinoid agonist, has been shown to inhibit HO formation in mouse models.
- In experiments, palovarotene significantly reduced the levels of activin A in HO tissues and decreased interactions among local cell populations, suggesting its potential as an effective treatment by targeting various mechanisms of bone formation in HO.